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first symptoms of EAE substantially increased the normal 
disease-associated expression of IFN-α, IFN-β, interferon 
regulatory factor-7 and IL-10 in CNS, and disease worsen-
ing was prevented for as long as IFN-α/β was expressed. 
In contrast, there was no therapeutic effect on EAE in poly 
I:C-treated IFN receptor-deficient mice. IFN-dependent 
microglial and astrocyte response included production of 
the chemokine CXCL10. These results show that Type I 
IFN induced within the CNS can play a protective role in 
EAE and highlight the role of endogenous type I IFN in 
mediating neuroprotection.
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Introduction
Interferon (IFN)-β and IFN-α constitute the Type I IFN 
family, members of which play a central role in antiviral 
immune responses and in regulation of inflammation [3, 
30]. They signal through a common receptor (IFNAR) 
to activate transcription of several genes including inter-
feron regulatory factor 7 (IRF7) and IRF9, which are also 
involved in the induction of Type I IFN [14, 30]. Impor-
tantly, IFN-β is used as a first-line treatment for multiple 
sclerosis (MS).
Type I IFN are induced by engagement of innate immune 
receptors, including toll-like receptors (TLR) and retinoic 
acid-inducible gene (RIG) I-like helicases (RLH). Innate 
receptors induce responses by detecting molecular struc-
tures shared by many pathogens as well as endogenous ago-
nists associated with tissue damage [19]. Pathogen-derived 
and experimental agonists such as the synthetic double-
stranded RNA analog polyinosinic–polycytidylic acid (poly 
Abstract The Type I interferons (IFN), beta (IFN-β) and 
the alpha family (IFN-α), act through a common receptor 
and have anti-inflammatory effects. IFN-β is used to treat 
multiple sclerosis (MS) and is effective against experimen-
tal autoimmune encephalomyelitis (EAE), an animal model 
for MS. Mice with EAE show elevated levels of Type I 
IFNs in the central nervous system (CNS), suggesting a 
role for endogenous Type I IFN during inflammation. How-
ever, the therapeutic benefit of Type I IFN produced in the 
CNS remains to be established. The aim of this study was to 
examine whether experimentally induced CNS-endogenous 
Type I IFN influences EAE. Using IFN-β reporter mice, we 
showed that direct administration of polyinosinic–polycyti-
dylic acid (poly I:C), a potent inducer of IFN-β, into the 
cerebrospinal fluid induced increased leukocyte numbers 
and transient upregulation of IFN-β in CD45/CD11b-pos-
itive cells located in the meninges and choroid plexus, as 
well as enhanced IFN-β expression by parenchymal micro-
glial cells. Intrathecal injection of poly I:C to mice showing 
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I:C) engage TLR3, melanoma differentiation-associated 
protein 5 (MDA5) and RIG-I and lead to cytokine synthesis 
and secretion, including IFN-α and IFN-β (IFN-α/β) [38].
Peripheral administration of poly I:C has been shown 
to suppress the progression of experimental autoimmune 
encephalomyelitis (EAE) [7, 36]. Whether the suppres-
sive effect of poly I:C on EAE involved CNS or peripheral 
action of IFN-α/β is not clear [7, 36]. Peripheral IFN-α/β 
may access the inflamed CNS [30]. IFN-β is dramatically 
increased in the CNS of mice with EAE [31], and Type I 
IFN response has been implicated in regulation of EAE 
[31, 32, 35]. Together, these findings suggest an important 
role for endogenous type I IFN within the CNS. However, 
there is a paucity of information about cellular sources and 
the action of IFN-α/β produced in the CNS.
The aim of this study was to examine the therapeutic 
role of IFN-α/β produced in the CNS during EAE. Direct 
administration of poly I:C into the cerebrospinal fluid 
(CSF) via the cisterna magna transiently induced IFN-β 
expression by myeloid cells in meninges and choroid 
plexus, and increased the expression of IFN-α/β by micro-
glia. Therapeutic inhibition of established EAE correlated 
temporally with IFN-α/β expression, and was IFNAR1 
and IFN-α/β dependent. Astrocytes and microglia upregu-
lated IFN-response genes and the IFNAR1-dependent 
chemokine CXCL10. IFN-α/β produced within the CNS, 
therefore, mediates endogenous neuroprotection.
Materials and methods
Mice
C57BL/6 mice were purchased from Taconic (Taconic 
Europe, Ry, Denmark). IFNAR1-KO mice (C57BL/6 back-
ground) [28] and transgenic GFAP-EGFP mice (FVB back-
ground) [29] originally from Drs. Marco Prinz, University 
of Freiburg, Germany and Helmut Kettenmann, Max-Del-
brück-Center for Molecular Medicine, Berlin, Germany, 
respectively, were bred and housed in the Biomedical 
Laboratory, University of Southern Denmark. Experiments 
were conducted in accordance with the national ethical 
committee (Animal Experiments Inspectorate under Dan-
ish Ministry of Food, Agriculture and Fisheries, The Dan-
ish Veterinary and Food Administration) (approval number 
2012-15-2934-00110).
IFN-βmob/mob mice [33] were obtained from Jackson 
Laboratory and Albino (C57BL/6-Tyrc−2J) IFN-β+/Δβ−
luc mice (IFN-β-luciferase reporter mice [21]) were bred 
and housed at the Department of Molecular Immunology, 
Helmholtz Centre for Infection Research, Braunschweig, 
Germany. Experiments using IFN-β+/Δβ−luc mice were per-
formed under approval number 33.9-42502-04-12/0968 
of local authority Niedersächsisches Landesamt für Ver-
braucherschutz und Lebensmittelsicherheit (LAVES).
EAE induction
C57BL/6 and IFNAR1-deficient mice were immunized 
with MOG p35-55, kindly provided by Mogens Nielsen at 
the Centre for Experimental Bioinformatics, Department 
of Biochemistry and Molecular Biology, University of 
Southern Denmark. Emulsions of MOG p35-55 (100 μg) 
and complete Freund’s adjuvant with heat-inactivated 
Mycobacterium tuberculosis (200 μg; Difco Laboratories, 
Detroit) were injected subcutaneously. Animals received an 
intraperitoneal injection of pertussis toxin (0.3 μg; Sigma-
Aldrich, Brøndby, Denmark) at the time of immunization 
and 2 days post-immunization, as described previously 
[26]. Mice were monitored for loss of body weight and 
EAE symptoms. The EAE grades were as follows: Grade 0, 
no signs of disease; Grade 1, weak or hooked tail; Grade 2, 
floppy tail indicating complete loss of tonus in tail; Grade 
3, floppy tail and hind limb paresis, Grade 4: floppy tail 
and unilateral hind limb paralysis; Grade 5, floppy tail and 
bilateral hind limb paralysis. For ethical reasons, mice were 
not allowed to reach grades higher than 5.
Intrathecal injection
Mice were anesthetized using isoflurane and the back of 
the head was shaved. A 30-gauge needle (bent at 55°, 2 mm 
from the tip) attached to a 50-µl Hamilton syringe was 
inserted between the skull and the cervical vertebra into 
the intrathecal space of the cisterna magna. Mice received 
intrathecal injection (10 µl) of poly I:C (Sigma-Aldrich, 
Copenhagen, Denmark) at 0, 3, 1, 3 and 10 mg/ml, or 
PBS. Intrathecal injection allows delivery of substances to 
the CNS with minimal trauma [1, 11, 25]. The mice were 
euthanized 6, 18 and 72 h post-injection with an overdose of 
sodium pentobarbital and subsequently perfused transcardi-
ally with PBS. For flow cytometric analysis, brains and spi-
nal cords were removed into ice cold Ca2+/Mg2+ free Hanks 
balanced salt solution (HBSS) before being dissociated.
For histology, mice were additionally perfused with 4 % 
PFA in PBS. After removal, brains and spinal cords were 
post-fixed in 4 % PFA, immersed in 30 % sucrose in PBS 
at 4 °C overnight, frozen with liquid nitrogen and stored at 
−80 °C until sections were cut on a cryostat.
Flow cytometric cell sorting
Brains and spinal cords from transgenic GFAP-EGFP mice 
were dissociated using the papain-based neural tissue dis-
sociation kit (Miltenyi Biotec, Germany). Myelin was sepa-
rated from the cells on a discontinuous Percoll gradient (GE 
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Healthcare Biosciences AB, Uppsala, Sweden) and the cells 
were washed and incubated with blocking solution contain-
ing HBSS, FBS (Sigma-Aldrich), anti-Fc receptor antibody 
(BD Biosciences, Brøndby, Denmark), hamster IgG (Jack-
son ImmunoResearch, West Grove, PA, USA), and sodium 
azide. The cells were then labeled with phycoerythrin (PE)-
conjugated anti-CD45 (BD Biosciences) for 15 min at 4 °C 
and propidium iodide (PI, Sigma-Aldrich) to detect micro-
glia/macrophages and non-viable cells, respectively.
Cells were sorted using a FACSVantage SE DiVa cell 
sorter (BD Biosciences). Astrocytes were defined as EGFP 
positive and CD45 negative (Fig. 6b). Microglia were 
defined as EGFP negative and CD45dim. Sorted astrocytes 
and microglia were re-analyzed by flow cytometry and 
quantitative real-time RT-PCR to verify purity.
Quantitative real‑time PCR (qRT‑PCR) of sorted cells
RNA extraction was performed using an ABI PRISM™ 
6700 Automated Nucleic Acid Workstation (Applied Biosys-
tems, Foster City, CA, USA) according to the manufacturer’s 
protocol for total RNA purification from cultured cells with 
including (optional) DNAse treatment or using a Trizol pro-
tocol as described previously [32]. The RNA was converted 
into cDNA using high-capacity cDNA reverse transcription 
kits (Applied Biosystems). qRT-PCR was performed using 
an ABI Prism 7300 sequence detection system (Applied 
Biosystems). 18S rRNA was used for normalization of gene 
expression [18]. Ct values were determined and ΔCt values 
were calculated by subtracting the average of Ct values of 
gene of interest from Ct value for the 18S. The relative gene 
expression was then calculated using 2−Ct method.
The following primer and probe sequences were used: 
CD68 (Forward GCTCCCTGTG TGTCTGATCTTG, 
Reverse GCCTTTTTGTGAGGACAGTCTTC, Probe 
CCGCTTATAGCCCAAGGA MGB), GFAP (Forward ACA 
GACTTTCTCCAACCTCCAGAT, Reverse GCCTTCT 
GACACGGATTTGGT, Probe CGAGAAACCAGCCTGG 
MGB), IRF-7 (Forward CACCCCCATCT TCGACTTCA, 
Reverse CCAAAACCCAGGTAGATGGTGTA, Probe 
CACTTTCTTCCGAG AACT MGB), IFN-β (Forward 
GCGTTCCTGCTGTGCTTCTC, Reverse TTGAAGTC 
CGCCCTGTAGGT, Probe CGGAAATGTCAGGAGCT 
MGB), IFN-α(B+6+12+14) (Forward AGGATGTGACCT 
GCCTCAGACT, Reverse GCTGGGCATCCACCTTCTC, 
Probe CTCTCTCCTGCCTGAAG MGB), CCL2 (Forward 
TCTGGGCCTGCTGTTCACA, Reverse ACTCATT GGGA 
TCATCTTGCT, Probe CTCAGCCAG ATGCAGTT MGB), 
CXCL10 (Forward GCCGT CATTTTCTGCCTCAT, 
Reverse GGCCCGTCATCGATATGG, Probe GGACTC 
AAGGGATCC MGB), IRF-9 (Forward ACAACTGAGG 
CCACCATTAGAGA, Reverse CACCACTCGGCCAC 
CATAG, Probe TGAACTCAGACTACTCGCT MGB), 
IL-10 (Forward GGTTGCCAAGCCTTATCGGA, Reverse 
ACCTGCTCCACTGCCTTGCT, Probe TGAGGCGCT 
GTCATCGATTTCTCCC TAMRA) IL-17A (Forward 
CTCCAGAAGGCCCTCAGACTAC, Reverse TGTGGTG 
GTCCAGCTTTCC, Probe ACTCTCCACCGCAATGA 
MGB), IFN-γ (Forward CATTGAAAGCCTAGAAAGTCT 
GAATAAC, Reverse TGGCTCTGCAGGATTTTCATG, 
Probe TCACCATCCTTTTGCCAGTTCCTCCAG MGB).
qRT-PCR analysis of mRNA for the astrocyte marker 
GFAP and the myeloid marker CD68 was used to verify puri-
ties. Sorted astrocytes with relative CD68/18S levels above 
10 were omitted and vice versa for microglia and GFAP.
Immunostaining
For identifying cellular localization of IFN-β, we used IFN-β/
YFP reporter mice. Tissue sections (16 µm) were rinsed in 
PBS containing 0.2 % Triton X-100 (PBST). The sections 
were incubated in blocking solution containing PBST and 
3 % BSA, and stained either with rabbit anti-GFP antibody 
(ab6556; Abcam), PE-conjugated rat anti-mouse CD45 (BD 
Biosciences), Cy3-conjugated anti-GFAP or anti-Mac-1/
CD11b (MCA711, Serotec, Oxford, UK). After 3 washes in 
PBST, sections were incubated with biotinylated goat anti-
rabbit (Abcam), Alexa-569 goat anti-rat or streptavidin-HRP. 
GFP signal was amplified with TSA fluorescein kits (Perki-
nElmer) according to the manufacturer’s instructions. Sections 
were incubated with DAPI and mounted using gelvatol [17].
Images were acquired using an Olympus DP71 digital 
camera mounted on an Olympus BX51 microscope (Olym-
pus, Ballerup, Denmark) and with Olympus FV1000MPE 
Confocal and Multiphoton Laser Scanning Microscope, 
Danish Molecular Biomedical Imaging Center (DaMBIC), 
University of Southern Denmark. Images were combined 
using Adobe Photoshop CS3 (Adobe Systems Denmark A/S, 
Copenhagen, Denmark) to visualize double-labeled cells.
Detection of luciferase
For in vivo imaging, IFN-β+/Δβ−luc mice were injected (i.v.) 
with D-luciferin (150 mg/kg), anesthetized using isoflurane 
and monitored using an IVIS 200 imaging system (Cali-
perLS). Photon flux was quantified using Living Image 4.4 
software (CaliperLS).
Results
Intrathecal poly I:C transiently induced IFN‑β in the 
CNS
Poly I:C was injected into CSF via the cisterna magna 
of reporter mice that express a luciferase gene under 
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the control of the IFN-β promoter [21]. In vivo imaging 
revealed CNS-restricted expression of IFN-β in response 
to poly I:C (Fig. 1a). The luciferase signal was expressed 
in brain and spinal cord and extended rostrally and cau-
dally from the site of injection. Expression was strongest 
at 4 h, was significantly reduced at 24 h (Fig. 1), and was 
undetectable at 48 h (not shown). The induction of IFN-β 
expression was dose dependent, and optimally induced by 
10 μg poly I:C (Supplementary Fig. 1).
IFN‑β was expressed by cells in the meninges 
and choroid plexus
In preference to luciferase staining [16], we used IFNβ/
yellow fluorescent protein (YFP) knock-in (IFN-βmob/mob) 
mice, which allow easy detection of IFN-β expression 
directly at the cellular level [33]. Six hours after poly I:C 
injection into the cisterna magna, brains and spinal cords 
were examined for IFN-β expression using an anti-GFP 
antibody which detects YFP [33]. Sparse IFN-β/YFP-
expressing cells were distributed in meninges in the brain 
(Fig. 1b, c), in spinal cord (Fig. 1d), and in choroid plexus 
(Fig. 1e). Despite rigorous searching, we could not find 
YFP+ cells within CNS parenchyma. IFN-β/YFP staining 
was not detected in CNS from PBS-injected mice. Con-
trol sections treated without primary antibody or with iso-
type-matched primary antibodies showed no staining (not 
shown). Preliminary analysis of liver and thymus showed 
no discernible change in the constitutive IFN-β signal [21], 
supporting a CNS-restricted effect of poly I:C (Supplemen-
tary Fig. 2).
IFN‑β was expressed by CD45+ and Mac1/CD11b+ 
cells
To identify cellular sources of IFN-β, we double-stained 
IFN-β/YFP+ cells for GFAP and Mac1/CD11b. Double 
immunostaining showed that IFN-β/YFP+ cells at 6 h 
post-poly I:C injection were positive for CD45 and Mac1/
CD11b (Fig. 2a–e). IFN-β/YFP+ cells did not co-localize 
with GFAP (Fig. 2f). This identifies extraparenchymal 
myeloid cells as a source of poly I:C-induced IFN-β.
Parenchymal microglia and CD45high leukocytes are 
sources of IFN‑α/β in CNS
Cellular source of IFN-β was further investigated using 
flow cytometry and cell sorting. A significant population 
Fig. 1  Intrathecal poly I:C induced IFN-β in the CNS. a IFN-β 
reporter mice received poly I:C by intrathecal injection and luciferase 
activity was visualized after 4 and 24 h. Poly I:C induced IFN-β in 
the brain and spinal cord at 4 and 24 h. IFN-β response was much 
stronger at 4 h than at 24 h. Bar graphs depict the quantification of 
luciferase activity at indicated time points (n = 4). Data were ana-
lyzed by two-tailed nonparametric Student’s t test followed by Mann–
Whitney test. Results are presented as mean ± SEM. *P < 0.05. Dis-
tribution of IFN-β-producing cells in the CNS. IFN-β/YFP+ staining 
(green) was observed in meninges around brain (b, c) and spinal cord 
(d) as well as choroid plexus (e), as indicated by red boxes on the 
central schematic. Nuclei were stained with DAPI (blue). Scale bars 
50 µm (b–e). CP choroid plexus in fourth ventricle, LC leptomenin-
geal cortex, LM leptomeningeal midbrain, LVMF leptomeningeal 
ventral median fissure. Original magnification 10×
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of CD45high cells was detected in perfused CNS from 
mice that had received intrathecal poly I:C 6 h previously 
(Fig. 3). Almost all of these were CD11b+. These are dis-
tinguished from parenchymal microglia by the lower level 
of CD45 staining on microglia (Fig. 3) [18]. CD45dim 
microglia are not detected using anti-CD45 immunostain-
ing in tissue sections by the protocol we have used. To 
ask whether microglia contribute to the IFN-β response 
and to confirm that the CD45high cells included the IFN-β-
producing cells identified in YFP reporter mice, CD45dim-
CD11b+ cells (microglia) and CD45high (leukocytes) were 
sorted and IFN-β mRNA was measured by qRT-PCR. 
Intrathecal poly I:C induced increased IFN-β expres-
sion over undetectable levels in sorted CD45high cells. 
Importantly, there was an approximate fourfold induction 
over already detectable levels of IFN-β mRNA expres-
sion in CD45dimCD11b+ microglia, and this was statisti-
cally significant (Fig. 3c). We also screened for IFN-α 
using a primer/probe set designed to recognize IFN-
α(B+6+12+14). IFN-α mRNA was detected in one out of 
four samples of microglia from PBS-treated mice and in 2 
out of 8 samples from poly I:C-treated mice (not shown). 
Fig. 2  Cellular sources of IFN-β in the CNS. a–c Double immu-
nostaining showed that IFN-β/YFP+ was induced in cells (green) 
that co-localized both with CD45 (red) and d with Mac1/CD11b 
(red), in mice treated with poly I:C. e Higher magnification of double 
positive YFP+ Mac1/CD11b+ cells in d (white box, magnification 
20×). f Poly I:C-induced IFN-β/YFP+ (green) stained cells within 
meninges did not co-localize with GFAP+ staining (red). DAPI 
(blue) shows nuclear staining. g–i IFN-β/YFP+ staining was not 
induced in CNS from a PBS-treated mouse. j IFN-β/YFP+ staining 
was absent in sections incubated with normal rabbit antibody. Scale 
bars 50 µm (a–d, g–j) and 20 µm (e, f). Original magnification was 
10×
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Thus, both extraparenchymal myeloid cells (leukocytes) 
and parenchymal microglia expressed IFN-α/β in response 
to poly I:C.
Therapeutic effect of intrathecal poly I:C on EAE
We then asked whether induction of endogenous IFN-α/β in 
the CNS would affect EAE. We immunized C57BL/6 mice 
with MOG p35-55. Day of onset was defined as first pres-
entation of symptoms, which in all cases was the loss of 
tail tonus. Mice were randomized on the day of onset with 
regard to treatment, and administered poly I:C or PBS into 
the cisterna magna. Mice were then evaluated for whether 
disease worsened, using conventional EAE clinical scoring.
The mean clinical score showed a significant increase 
from 24 to 48 h in PBS-treated mice, but did not change in 
mice that received poly I:C, until 48 h after disease onset 
(Fig. 4a; Supplementary Fig. 3). This transient therapeu-
tic effect of poly I:C coincided with detection of IFN-β in 
reporter mice (Fig. 1a) and IFN-α/β by RT-PCR (Fig. 4a, 
b). Furthermore, therapeutic effect was not seen in poly 
I:C-treated mice lacking the IFNAR1 receptor for Type 
I IFN, where symptoms of disease worsened similarly to 
PBS-treated C57BL/6 mice (Fig. 4a).
Levels of IFN-β and IRF-7 mRNA were elevated in 
mice with EAE compared to healthy controls (Fig. 4c, 
d). Interestingly, there was no difference in IFN-α levels. 
Poly I:C treatment of those mice additionally increased 
IFN-α/β levels, although not to statistical significance for 
IFN-β (Fig. 4b, c). In contrast to IFN-α/β, IRF7 induction 
was prolonged and still increasing at 18 h after poly I:C 
treatment, as expected since IRF7 is an IFN target gene 
(Fig. 4d). A preliminary experiment with IFN-β-deficient 
mice showed no Type I IFN induction nor suppression of 
EAE by poly I:C treatment (data not shown). Thus, the 
alleviation of EAE due to intrathecal poly I:C treatment 
was accompanied by increased expression of IFN-α/β and 
IRF7, and dependent on IFN-α/β signaling.
Fig. 3  Poly I:C induced IFN-β in leukocytes. a A representative 
flow cytometry profile showing CD45high (leukocytes) and CD45dim-
CD11b+ (microglia) cell populations isolated from the CNS of mice 
treated with PBS or poly I:C, 6 h previously. b Number of CD45high 
cells isolated from mice treated with poly I:C (n = 5) compared to 
PBS (n = 3). c CD45high (leukocytes) and CD45dimCD11b+ cells 
(microglia) were sorted, pooled and IFN-β mRNA was measured 
by qRT-PCR. Bar graphs show IFN-β gene expression in sorted 
CD45dimCD11b+ microglia (n = 6) from poly I:C-treated mice com-
pared to microglia (n = 6) from PBS-treated mice, in which IFN-β 
was also detected at a low level. Intrathecal poly I:C induced detect-
able IFN-β expression in sorted CD45high cells (n = 6), whereas 
IFN-β expression was not detected at all in sorted CD45high from 
PBS-treated mice (n = 6). Data were analyzed by two-tailed nonpara-
metric Student’s t test followed by Mann–Whitney test. Results are 
presented as mean ± SEM. *P < 0.05
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No effect of CNS‑endogenous IFN‑α/β on established 
EAE pathology
We have shown previously that lack of IRF7 exacerbates EAE 
and results in increased leukocyte infiltration [32]. We asked 
whether the protective function of endogenous IFN-α/β in 
EAE reflected effects on leukocyte infiltration. Mice entered 
the experiment with EAE and therefore showed increased 
numbers of CD45high leukocytes in the CNS. Poly I:C treat-
ment did not noticeably affect this infiltration 6 h after admin-
istration (Fig. 5a). Similarly, histologically detected infiltra-
tion in spinal cord showed no obvious difference between 
PBS and poly I:C treatment at one day (Fig. 5b).
Levels of IL-17 and IFN-γ message were elevated in the 
CNS of mice with EAE, and were not affected by poly I:C 
treatment (Fig. 5c). In contrast, IL-10 expression in CNS 
was significantly elevated 18 h after poly I:C injection 
(Fig. 5d).
Intrathecally induced IFN‑α/β stimulated glial 
chemokine response
The chemokines CCL2 and CXCL10 are both impli-
cated in EAE [22, 24]. They are produced by activated 
microglia and astrocytes, and their induction has been 
reported to be dependent on or associated with Type I 
IFN signaling [18, 36]. Expression of both chemokines 
was significantly increased in diseased animals (Fig. 6a). 
Poly I:C treatment of those mice resulted in an addi-
tional transient elevation of these two chemokines 
(Fig. 6a). To investigate whether this IFN-α/β-induced 
chemokine expression involved glial cells, we adminis-
tered poly I:C intrathecally to GFAP promoter-driven 
EGFP reporter mice, to allow isolation of astrocytes by 
cell sorting (Fig. 6b, c, d). Microglia were sorted by rela-
tive CD45 levels, as before. IRF7 and IRF9 levels were 
elevated in astrocytes and microglia (IRF7 only) at 18 h 
after poly I:C injection (Fig. 6e), indicating that both 
glial cell types had responded to IFN-α/β. The relative 
IRF7 expression in response to poly I:C was higher in 
microglia compared to astrocytes (Fig. 6e). The IFN-α/β 
response was accompanied by a significant increase of 
CXCL10 in both astrocytes and microglia (Fig. 6e). This 
CXCL10 induction was not seen in IFNAR1-deficient 
mice (Fig. 6f), consistent with our previous study [18]. 
Thus, CNS-restricted IFN-α/β, from infiltrating myeloid 
and resident microglia, induced microglial and astroglial 
response and inhibited EAE.
Fig. 4  Intrathecal induction of IFN-α/β inhibited EAE. C57BL/6 
and IFNAR1-deficient mice were immunized with MOG p35-55 and 
administered poly I:C or PBS by injection into the cisterna magna 
on the first day (day 0) with symptoms of EAE. a Shows pooled 
data from four independent experiments (n = 22). The mean clini-
cal score did not change until the 48 h time point in mice that had 
received poly I:C (closed squares), whereas the control PBS-treated 
mice showed a significant increase in clinical score at both 24 
(P < 0.01) and 48 h (P < 0.001) (open squares). The mean clinical 
score increased significantly at 24 (P < 0.05) and 48 h (P < 0.05) 
in IFNAR1-deficient mice (n = 7) that were given intrathecal poly 
I:C (closed triangles). Clinical scores at 24 h in PBS- and poly I:C-
treated C57BL/6 mice were significantly different from each other 
(P < 0.05), whereas there was no difference between PBS- and poly 
I:C-treated IFNAR1-deficient mice at 24 h. b IFN-α message was sig-
nificantly increased at 4 h after poly I:C treatment of mice with EAE. 
Mice with EAE had elevated levels of IFN-β (P < 0.05) (c) and IRF7 
(P < 0.005) (d) in the CNS compared to unmanipulated (unm) mice. 
Levels of mRNA for IFN-β were increased at 4 h after poly I:C treat-
ment of mice with EAE but not to significance (c). Levels of IRF7 
message were significantly increased at 4 and 18 h post-poly I:C 
treatment (d). Data were analyzed by two-tailed nonparametric Stu-
dent’s t test followed by Mann–Whitney test. Results are presented as 
mean ± SEM. *P < 0.05, **P < 0.01
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Discussion
We have shown that Type I IFN can be induced within the 
CNS and is effective against EAE, an MS-like autoimmune 
inflammatory disease. The cell source of IFN-α/β included 
parenchymal microglia and extraparenchymal myeloid 
cells. Expression of IL-10 was increased and IFN-α/β-
dependent microglial and astrocyte response included pro-
duction of the chemokine CXCL10. These findings identify 
the potential for CNS-endogenous immunoregulation in 
treatment of MS.
Many cells have the capacity to produce Type I IFN 
and so production of IFN-α/β in the CNS is not a priori 
unexpected. However, the therapeutic potential of CNS-
restricted Type I IFN induction is unclear. Although Type I 
IFN administered in the periphery can to some level access 
the CNS, the effects of IFN-β therapy in MS can largely be 
explained as reflecting peripheral action [30]. At the same 
time, intra-CNS synthesis has been difficult to exclude 
in studies examining access of this cytokine to the CNS 
(see [30]). In our study, the IFN response was short-lived, 
reflecting a combination of stimulus-dependent activation 
and clearance of the ligand.
Studies of bone marrow chimeras involving lineage-
specific disruption of the gene for the Type I IFN receptor, 
as well as adoptive transfers of encephalitogenic T cells in 
mice lacking IFNAR1 or IFN-β, have shown a role for IFN 
response within the CNS in controlling EAE [31, 35]. Prinz 
and colleagues [31] showed that IFN-β was selectively pro-
duced within the CNS in mice with EAE, and that response 
of myeloid cells (which would include microglia) was criti-
cal to protection. However, the cellular source of IFN-β 
within the CNS was not addressed.
Making use of sensitive reporter systems, we show 
that an innate immune ligand can stimulate myeloid cells 
in the CNS to produce IFN-β. The IFN-β/YFP+ extra-
parenchymal cells that we identified expressed CD11b and 
CD45 and therefore were likely to be CD11b+ DC or mac-
rophages. The demonstration that an intrathecal stimulus 
can mobilize an extraparenchymal source of immunoreg-
ulatory cytokine with such rapid kinetics is striking and 
likely physiologically relevant.
The constitutive expression of IFN-α/β mRNA by 
microglia from unstimulated CNS adds to the evidence that 
CNS-resident microglia are active under normal circum-
stances [13] and that they may play a regulatory role. In 
a study by Prinz et al. [31], it was noticeable that IFN-β 
could be detected by ELISA in CNS of mice without EAE, 
and it was suggested that microglia could be a source. We 
have previously noted elevated levels of IRF7 in microglial 
Fig. 5  Leukocytes in CNS of 
mice with EAE after treat-
ment with PBS or poly I:C. 
a Flow cytometry analysis of 
leukocytes (CD45high) in mice 
with EAE. Infiltration was not 
affected by poly I:C (n = 5) at 
6 h. b Images show hematoxy-
lin and eosin staining of spinal 
cord sections from mice with 
EAE 1 day after PBS or poly 
I:C treatment (original magnifi-
cation is 4×). Black boxes show 
higher magnification (20×) of 
selected areas with infiltrates. 
Scale bars 50 µm. c Levels of 
IL-17 and IFN-γ mRNA were 
elevated in CNS of mice with 
EAE, but were not affected by 
poly I:C treatment at indicated 
times. ND not detected. d Lev-
els of IL-10 message in CNS 
were significantly increased at 
18 h in response to poly I:C. 
Number of mice was between 4 
and 5 in each group
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Fig. 6  Intrathecal induction of IFN-β induced response in microglia 
and astrocytes. a Mice with EAE had elevated levels of CCL2 and 
CXCL10 compared to unmanipulated (unm) mice. Intrathecal admin-
istration of poly I:C transiently induced both CCL2 and CXCL10 
gene expression in CNS. Expression was highest at 4 h, and reduced 
to levels corresponding to levels in control mice, at 18 h. b Repre-
sentative flow cytometry profiles for cells isolated from EGFP-GFAP 
mice. Microglia and astrocytes were sorted as CD45dimEGFP− and 
CD45−EGFP+ cells, respectively. Sorted astrocytes and microglia 
were validated by analysis of expression of marker genes GFAP (c) 
and CD68 (d), respectively. Number of mice for flow cytometry was 
between 6 and 12 in each group, and the experiment was repeated 
three times independently. e Intrathecal injection of poly I:C induced 
upregulation of IRF7 in both microglia and astrocytes. Sorted micro-
glia from naïve mice expressed endogenously higher levels of IRF9 
mRNA than astrocytes. Poly I:C induced IRF9 in astrocytes, not in 
microglia. Sorted microglia from naïve mice expressed endogenously 
higher levels of CCL2 mRNA than astrocytes. In microglia and astro-
cytes poly I:C did not induce changes in CCL2 mRNA expression, 
but induced increased CXCL10 in both microglia and astrocytes. 
f The upregulation of CXCL10 mRNA in response to poly I:C was 
IFNAR1 dependent. Data were analyzed by two-tailed nonparamet-
ric Student’s t test followed by Mann–Whitney test. Results are pre-
sented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001
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cells [18], which can indicate both IFN production and 
response.
Kocur et al. (Acta Neuropathol Commun, in press) have 
identified microglia as major producers of endogenous 
IFN-β in the CNS of mice with EAE, and that IFN-β pro-
ducing microglia (treated with poly I:C) mediated clear-
ance of myelin debris in organotypic slice cultures. They 
also found that in vitro treatment of microglia with IFN-β 
regulates their myelin phagocytosis. Together their find-
ings emphasize a protective role for IFN-β in EAE, which 
is in line with our findings. Unlike Kocur et al., we did not 
examine IFN-β/YFP mice with EAE. Intracisterna magna 
injection of poly I:C to otherwise unmanipulated mice 
induced detectable YFP in extraparenchymal myeloid cells 
but not in parenchymal microglia. The fourfold induction 
of IFN-β mRNA by poly I:C that we show in microglia was 
not sufficient to induce detectable YFP in reporter mice. 
This contrasts with Kocur et al.’s detection of peri-ventricu-
lar microglia following intracerebroventricular injection of 
poly I:C, which may be explained in our case by the lack of 
tissue trauma and accompanying glial response when using 
the ependymal route of injection [2, 23].
The extent to which microglial IFN-α/β contributed 
to IFNAR1-dependent alleviation of EAE remains to be 
determined. Clearly, the microglial IFN-β detected by 
Kocur et al. was not sufficient to prevent EAE and we must 
assume that the additional contribution from poly I:C-
induced microglia plus extraparenchymal myeloid cells 
tipped the balance in our study, and IFN-α may also have 
had effect. Direct test of the role of IFN-α is hindered by 
lack of reporter or knockout animals for this multigenic 
family, as well as that induction of IFN-α is impaired in 
IFN-β-deficient mice [8, 10]. Ability to access CNS-innate 
IFN-driven regulatory programs represents an attractive tar-
get for potential therapy in MS and other neurological dis-
eases. Some diseases such as Neuromyelitis optica may be 
worsened by IFN-β [30], but the EAE model we have stud-
ied neither involves aquaporin IV antibodies nor is depend-
ent on an antibody response [34].
Peripheral administration of TLR3/RIG-I/RLH ligands 
has been shown by others to suppress or prevent EAE 
[7, 36, 37]. Whether poly I:C acted via TLR3 or RIG-I/
MDA5 was not critical to interpretation in our study. 
Tzima et al. [37] demonstrated that peripheral administra-
tion of poly I:C suppressed clinical signs of EAE in mice, 
and that myeloid heme oxygenase-1 played a critical role 
in this response through IRF3 signaling and endogenous 
IFN-β induction. Touil et al. [36] reported that CCL2 was 
induced as a consequence of peripheral poly I:C injection 
that also suppressed EAE, and that CCL2 production was 
blocked after neutralization of IFN-β, arguing for Type I 
IFN dependence. However, that was not the case in another 
study, in which the chemokines CCL2 and CXCL10 were 
peripherally induced at increased levels compared to wild-
type controls in EAE in IFNAR1-deficient mice [31]. We 
did not observe induction of CCL2 in microglia or astro-
cytes by intrathecal poly I:C, though levels were transiently 
increased in whole CNS. Although CCL2-deficient mice 
are reported to be resistant to EAE [15], transgenic overex-
pression of CCL2 in the CNS was reported to prevent EAE 
[9]. We have published that transgenic mice overexpressing 
CCL2 show pronounced impairment of T cell development 
and are consequently resistant to EAE [5]. Touil et al. [36] 
showed that treatment of mice with neutralizing antibody 
against CCL2 reversed the suppressive effect of peripher-
ally administered poly I:C on EAE.
In a previous study of Type I IFN dependence of glial 
responses following synaptic degeneration in the dentate 
gyrus, we could show IFNAR1 dependence of CXCL10 
production but not of CCL2 [18]. Whether the elevated 
CXCL10 that we observed here played any role in EAE 
amelioration was not specifically addressed. A number of 
reports suggest that this chemokine or signaling through its 
principal receptor CXCR3 may be protective in EAE, but 
there are also opposing data [27].
We have shown that induction of Type I IFN within 
the CNS has therapeutic potential against EAE, an MS-
like disease. As far as we know, this is the first study to 
use intrathecal induction of IFN-α/β in an EAE therapeu-
tic mode. Our findings of elevated constitutive microglial 
expression of IFN-α/β mRNA as well as rapid mobilization 
of cells producing higher levels of cytokine are consistent 
with a natural role for IFN-α/β in CNS homeostasis that 
can be exploited for therapeutic benefit. The mechanism for 
EAE suppression by endogenous Type I IFN is therefore 
of interest. It was intrinsic to our experimental design that 
infiltration should have initiated before induction of IFN, 
as would also be the case if therapeutic induction was to 
be considered. In contrast to peripherally applied IFN-β in 
MS, for which mechanism is reviewed in [30], the effect 
of endogenous Type I IFN is a priori unlikely to involve 
inhibition of leukocyte infiltration, as supported by our data 
showing no effect on either histologically or flow cytomet-
rically detected infiltration. Furthermore, we did not detect 
any effect on the inflammatory status of encephalitogenic 
T cells, as measured by production of the Th1- and Th17-
associated cytokines IFN-γ and IL-17, presumably because 
such cytokine profiles were already committed at the time 
of IFN induction. We consider the most likely mechanism 
of suppression to be via action on glial cells to modify the 
local milieu. Both microglia and astrocytes upregulated 
IRF7 early, and we showed upregulation of IL-10 as well as 
glial-derived CXCL10.
Interleukin-10 is implicated in suppression of MS and 
EAE as well as other inflammatory autoimmune patholo-
gies, acting via regulation of cytokine, antigen presenting 
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cell and glial response and promoting anti-inflammatory 
pathways [20]. Although the increase in IL-10 only became 
statistically significant at 18 h, it cannot be excluded as a 
potential regulator at earlier times. IL-10-deficient mice 
develop more severe EAE [4]. Guo et al. [12] have shown 
that IFNAR1-deficient mice had reduced IL-10 expres-
sion, and in a recent report they suggested that IFN-β may 
induce T cells to produce IL-10, which in turn negatively 
regulates Th17-associated autoimmune inflammation [39]. 
Type I IFN can also exert anti-inflammatory effect via the 
induction of IL-10 from macrophages [6]. Flow cytometry 
data showed that the great majority of leukocytes were 
myeloid cells expressing CD11b. Together with the lack 
of effect on IL-17 message, our results suggest that mac-
rophages contributed to the increased level of IL-10. It may 
be relevant that whereas systemically administered IL-10 
was only modestly effective against EAE, intranasal or 
intracerebroventricular delivery was more promising and 
included evidence of microglial involvement in disease 
alleviation (reviewed in [20]). More than one report has 
shown that the Type I IFN-dependent chemokine CXCL10 
or its principal receptor CXCR3 can modulate EAE [27], 
and it is notable that this chemokine was induced in both 
microglia and astrocytes and at early time points. Our find-
ings therefore support a role for IFN-producing microglia 
and macrophages and IFN-signaled glial cells.
Our findings add to evidence for a prominent microglial 
role in endogenous protection, both via production of Type 
I IFN, which we like others (Kocur et al. Acta Neuropathol 
Commun, in press) have now directly shown, as well as 
induction of candidate response modulators. An ancillary 
role for astrocytes as IFN-signaled cells that can also pro-
duce response modulators is likely to be important as well, 
especially given their strategic location at the blood–brain 
barrier.
The prospect for therapeutic application of such endog-
enous regulation of neuroinflammation will depend on 
identification of agonists that can access the appropriate 
response regulatory glial cells and sustain continued pro-
duction of IFN and other regulators, sufficient to maintain 
neuroprotection. This is a challenge for the future.
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